Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231118209> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4231118209 endingPage "2051" @default.
- W4231118209 startingPage "2037" @default.
- W4231118209 abstract "We present continuous and group sequential designs for phase II clinical trials based on the sequential conditional probability ratio test (SCPRT). The SCPRT is derived from a conditional likelihood ratio, where the conditioning is on what the corresponding (reference) fixed sample size test (RFSST) would achieve. In other words, we obtain the sequential design by controlling the maximum probability that the SCPRT does not agree with the RFSST. We shall discuss the difference between SCPRT and stochastic curtailment which also uses the concept of conditional distribution. We show that the power function of the SCPRT is virtually the same as that of the RFSST and its average sample numbers (ASNs) are close to those of Wald's sequential probability ratio test (SPRT), whereas its maximum sample size is no greater than that of the RFSST. Thus the SCPRT has all the desirable properties, such as allowing the use of the RFSST at the last analysis, of the Fleming procedure for phase II trials. The SCPRT, however, preserves the power function of the RFSST better and gives us the option for continuous monitoring. Our recommendation, therefore, is to use a group SCPRT boundary (for interim analyses performed as scheduled) embedded in a continuous SCPRT boundary (for unplanned interim analyses and analyses at times based on data trends). We provide as well a bias-adjusted estimator of the success rate after sequential stopping. We illustrate the method with several examples. The method applies to any single-arm clinical trial with binary endpoints, such as the classic paired design." @default.
- W4231118209 created "2022-05-11" @default.
- W4231118209 creator A5018924582 @default.
- W4231118209 creator A5064562354 @default.
- W4231118209 date "1996-10-15" @default.
- W4231118209 modified "2023-09-26" @default.
- W4231118209 title "CONTINUOUS AND GROUP SEQUENTIAL CONDITIONAL PROBABILITY RATIO TESTS FOR PHASE II CLINICAL TRIALS" @default.
- W4231118209 doi "https://doi.org/10.1002/(sici)1097-0258(19961015)15:19<2037::aid-sim339>3.3.co;2-q" @default.
- W4231118209 hasPublicationYear "1996" @default.
- W4231118209 type Work @default.
- W4231118209 citedByCount "0" @default.
- W4231118209 crossrefType "journal-article" @default.
- W4231118209 hasAuthorship W4231118209A5018924582 @default.
- W4231118209 hasAuthorship W4231118209A5064562354 @default.
- W4231118209 hasConcept C105795698 @default.
- W4231118209 hasConcept C129848803 @default.
- W4231118209 hasConcept C134306372 @default.
- W4231118209 hasConcept C141071460 @default.
- W4231118209 hasConcept C154945302 @default.
- W4231118209 hasConcept C166957645 @default.
- W4231118209 hasConcept C168563851 @default.
- W4231118209 hasConcept C185429906 @default.
- W4231118209 hasConcept C2776957806 @default.
- W4231118209 hasConcept C33923547 @default.
- W4231118209 hasConcept C34602496 @default.
- W4231118209 hasConcept C40696583 @default.
- W4231118209 hasConcept C41008148 @default.
- W4231118209 hasConcept C43555835 @default.
- W4231118209 hasConcept C44249647 @default.
- W4231118209 hasConcept C44492722 @default.
- W4231118209 hasConcept C50644808 @default.
- W4231118209 hasConcept C5465570 @default.
- W4231118209 hasConcept C61943457 @default.
- W4231118209 hasConcept C62354387 @default.
- W4231118209 hasConcept C71924100 @default.
- W4231118209 hasConcept C80478641 @default.
- W4231118209 hasConcept C95457728 @default.
- W4231118209 hasConceptScore W4231118209C105795698 @default.
- W4231118209 hasConceptScore W4231118209C129848803 @default.
- W4231118209 hasConceptScore W4231118209C134306372 @default.
- W4231118209 hasConceptScore W4231118209C141071460 @default.
- W4231118209 hasConceptScore W4231118209C154945302 @default.
- W4231118209 hasConceptScore W4231118209C166957645 @default.
- W4231118209 hasConceptScore W4231118209C168563851 @default.
- W4231118209 hasConceptScore W4231118209C185429906 @default.
- W4231118209 hasConceptScore W4231118209C2776957806 @default.
- W4231118209 hasConceptScore W4231118209C33923547 @default.
- W4231118209 hasConceptScore W4231118209C34602496 @default.
- W4231118209 hasConceptScore W4231118209C40696583 @default.
- W4231118209 hasConceptScore W4231118209C41008148 @default.
- W4231118209 hasConceptScore W4231118209C43555835 @default.
- W4231118209 hasConceptScore W4231118209C44249647 @default.
- W4231118209 hasConceptScore W4231118209C44492722 @default.
- W4231118209 hasConceptScore W4231118209C50644808 @default.
- W4231118209 hasConceptScore W4231118209C5465570 @default.
- W4231118209 hasConceptScore W4231118209C61943457 @default.
- W4231118209 hasConceptScore W4231118209C62354387 @default.
- W4231118209 hasConceptScore W4231118209C71924100 @default.
- W4231118209 hasConceptScore W4231118209C80478641 @default.
- W4231118209 hasConceptScore W4231118209C95457728 @default.
- W4231118209 hasIssue "19" @default.
- W4231118209 hasLocation W42311182091 @default.
- W4231118209 hasOpenAccess W4231118209 @default.
- W4231118209 hasPrimaryLocation W42311182091 @default.
- W4231118209 hasRelatedWork W1605150308 @default.
- W4231118209 hasRelatedWork W1973147602 @default.
- W4231118209 hasRelatedWork W2000120472 @default.
- W4231118209 hasRelatedWork W2033812080 @default.
- W4231118209 hasRelatedWork W2090966916 @default.
- W4231118209 hasRelatedWork W2103055533 @default.
- W4231118209 hasRelatedWork W2475316851 @default.
- W4231118209 hasRelatedWork W3135949750 @default.
- W4231118209 hasRelatedWork W4224222694 @default.
- W4231118209 hasRelatedWork W4231118209 @default.
- W4231118209 hasVolume "15" @default.
- W4231118209 isParatext "false" @default.
- W4231118209 isRetracted "false" @default.
- W4231118209 workType "article" @default.